Greenland Mines Ltd. (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent, which protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies, includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The Canadian patent expands the company’s intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. This development is significant as it strengthens Greenland Mines' position in the biotechnology sector, particularly in the race to develop effective treatments for debilitating neurological conditions that currently have limited therapeutic options. The patent provides a competitive edge by protecting the company's proprietary technology in a key market, potentially paving the way for future collaborations or licensing agreements.
Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year. The progression of these candidates underscores the company's commitment to advancing its pipeline toward clinical trials. KLTO-202 is specifically noted for its primary indication for ALS, a devastating neurodegenerative disease with no cure. The advancement to GMP manufacturing is a critical step in ensuring the therapy meets regulatory standards for human use.
The news matters because neurodegenerative diseases represent a growing global health crisis, with aging populations driving increased prevalence. Current treatments largely manage symptoms rather than address underlying causes. Klotho gene therapy offers a novel approach by targeting the biological pathways involved in cognitive decline and neurodegeneration. If successful, these therapies could transform the treatment landscape for millions of patients worldwide. For the industry, the patent validates the potential of Klotho as a therapeutic target and could spur further investment in gene therapy research.
Greenland Mines operates with two divisions: mining and biotech. The biotech division focuses on Klotho-based therapies, while the mining division explores rare earth materials in Greenland. The company’s strategy is centered on building a multi-asset platform, with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities. This dual focus may provide diversified revenue streams, though the biotech division's success hinges on regulatory and clinical outcomes.
For more details, the full press release is available at https://ibn.fm/x2pHAA. Investors seeking the latest news and updates relating to GRML can visit the company’s newsroom at https://ibn.fm/GRML.
